While there are an increasing number of reports on the limited role of most widely used biomarkers, such as the assessment of serum CgA levels [140,142], as well as increased reports of newer tumor marketers such as the assessment of circulated gene transcripts [NETest, subsets of NETest] [130,132], or circulating miRNA/lncRNAs/circulating tumor cells, etc. [397,398,399,400,401], at present none are routinely used and it generally remains unclear when these should be routinely used [136]. This evidence concerns the gene CGA and neoplasm.